BioRestorative Therapies Announces SBIR Phase I Grant to Explore Therapeutic Effects of ThermoStem Targeting Polycystic Ovarian Syndrome As an Indication

BioRestorative Therapies Announces SBIR Phase I Grant to Explore Therapeutic Effects of ThermoStem Targeting Polycystic Ovarian Syndrome As an Indication

BioRestorative Therapies, Inc. (‘BioRestorative’, ‘BRTX’ or the ‘Company’) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, announced today that it has received a Innovation Research for Small Businesses (SBIR) Grant Phase I of the Eunice Kennedy Shriver National Institute of Child Health and Human Development of National Institutes of Health. This collaborative research … Read more

BioRestorative Therapies Enters into Agreement with Regenexx, Granting BRTX Exclusive License Rights to Intellectual Property Related to the Development and Commercialization of its BRTX-100 Disc Program to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies Enters into Agreement with Regenexx, Granting BRTX Exclusive License Rights to Intellectual Property Related to the Development and Commercialization of its BRTX-100 Disc Program to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. (‘BioRestorative’ or the ‘Company’) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx to the Company for intellectual property developed to treat chronic lumbar disc disease have become exclusive. The intellectual property now exclusively licensed … Read more

BioRestorative Therapies Enters into Agreement with Regenexx, Granting BRTX Exclusive License Rights to Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies Enters into Agreement with Regenexx, Granting BRTX Exclusive License Rights to Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

— Intellectual property provides a cell-based therapeutic platform designed to target all avascular sites— MELVILLE, New York, Dec. 5, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorer” or the “Company”) (NASDAQ: BRTX)a clinical-stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx … Read more

Aquestive Therapeutics Announces Publication of Crossover Study of Dietary Effect of Diazepam Nasal Spray in Epilepsy

Aquestive Therapeutics Announces Publication of Crossover Study of Dietary Effect of Diazepam Nasal Spray in Epilepsy

Peer-reviewed data indicate that food significantly decreases and delays the absorption of diazepam dosed via nasal spray WARREN, NJ, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company that advances current standards of care to solve patient problems by simplifying delivery methods complexes, announced today the publication of a pharmacokinetic … Read more

Vistagen announces publication on cells demonstrating the potential of AV-101 to treat levodopa-induced dyskinesia in patients with Parkinson’s disease

Vistagen announces publication on cells demonstrating the potential of AV-101 to treat levodopa-induced dyskinesia in patients with Parkinson’s disease

Vistagen (NASDAQ: VTGN), a late-stage clinical biopharmaceutical company that aims to transform the treatment landscape for people living with anxiety, depression and other central nervous system (CNS) disorders, today announced the publication of positive results from a preclinical study of the effects of AV-101, its oral NMDA receptor glycine site antagonist, in a widely used … Read more

TIVIC HEALTH SYSTEMS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

TIVIC HEALTH SYSTEMS, INC.  Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

The following discussion and analysis of our financial condition and results of operations should be read together with the interim condensed financial statements and related notes included elsewhere in this Quarterly Report on Form 10­Q, as well as our audited financial statements and related notes as disclosed in our Annual Report on Form 10­K for … Read more

LUCIRA HEALTH, INC. Discussion and analysis of management’s financial situation and results of operations. (Form 10-Q)

LUCIRA HEALTH, INC.  Discussion and analysis of management’s financial situation and results of operations.  (Form 10-Q)

The unaudited condensed financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2021 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are … Read more

SONOMA PHARMACEUTICALS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

SONOMA PHARMACEUTICALS, INC.  Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q as of September 30, 2022 and our audited consolidated financial statements for the year ended March 31, 2022 included … Read more

REVELATION BIOSCIENCES, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

REVELATION BIOSCIENCES, INC.  Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements and the notes included elsewhere in the Form 10-Q. The following discussion contains forward-looking statements that involve certain risks and uncertainties. Our actual results could differ materially from those discussed in these statements. Factors that … Read more

DISCUSSION AND ANALYSIS OF THE MANAGEMENT OF VISTAGEN THERAPEUTICS, INC. ON FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

DISCUSSION AND ANALYSIS OF THE MANAGEMENT OF VISTAGEN THERAPEUTICS, INC.  ON FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q (Report) includes forward-looking statements. All statements contained in this Report other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” … Read more